H.U. Group Holdings, Inc., together with its subsidiaries, operates healthcare business in Japan, the United States, Europe, and internationally. The Lab Testing and Its Related Services segment collects specimens from medical offices, clinics, and hospitals, and conducts various tests at its laboratories. The segment also provides precision of the tests, pre-trial setup work, specimen collection and transport, measuring, result reports, and data management services for support in research and development of medicine. The In Vitro Diagnostics segment is involved in the provision of cerebrospinal fluid reagent, compatible with its automated chemiluminescent enzyme immunoassay system; development of blood-based reagents, as well as biomarkers specifically for neurodegenerative diseases, such as Alzheimer's. This segment also supplies key raw materials to global in-vitro diagnostics companies through a CDMO business model; offers Lumipulse, an automated chemiluminescence enzyme immunoassay system that offers reagents; and rapid diagnostics kits that serves as a platform for testing infectious diseases such as influenza and COVID-19. The Healthcare-related Services segment provides in-house sterilization services at the central supply rooms in hospitals and external sterilization at the sterilization centers; and offers operating and endoscopy room support, medical equipment maintenance and inspection, and logistics management and transportation services. This segment also engages in the sale of medical equipment, supplies, and consumables related to central supply and operating rooms; provision of home medical care and nursing services; and rental of nursing care equipment, such as wheelchairs and nursing beds. The company was formerly known as Miraca Holdings Inc. and changed its name to H.U. Group Holdings, Inc. in July 2020. H.U. Group Holdings, Inc. was incorporated in 1950 and is headquartered in Tokyo, Japan. Address: Shinjuku Mitsui Building, Tokyo, Japan, 163-0408